Role of maintenance immunosuppression and methylprednisolone in OKT3-induced cytokine release.
Peces
R
R
Service of Nephrology, Hospital Covadonga, Oviedo, Spain.
Urra
J M
JM
Gorostidi
M
M
López-Larrea
C
C
D006084:Graft Rejection / Q000276:immunology / Q000517:prevention & control*; D006085:Graft Survival / Q000187:drug effects* / Q000276:immunology; D006801:Humans; D007166:Immunosuppressive Agents / Q000008:administration & dosage*; D015850:Interleukin-6 / Q000097:blood*; D007677:Kidney Function Tests; D016030:Kidney Transplantation / Q000276:immunology*; D007958:Leukocyte Count / Q000187:drug effects; D008775:Methylprednisolone / Q000008:administration & dosage*; D016853:Muromonab-CD3 / Q000008:administration & dosage*; D011183:Postoperative Complications / Q000276:immunology / Q000517:prevention & control*; D014409:Tumor Necrosis Factor-alpha / Q000032:analysis*
D007166:Immunosuppressive Agents; D015850:Interleukin-6; D016853:Muromonab-CD3; D014409:Tumor Necrosis Factor-alpha; D008775:Methylprednisolone